Dr Reddys Labs unveils Treprostinil Injection in US

Hyderabad: Dr. Reddy’s Laboratories Ltd. has announced the launch of Treprostinil Injection in the U.S. market, a therapeutic equivalent generic
version of Remodulin (treprostinil) Injection, approved by U. S. Food and Drug Administration (USFDA). 

Treprostinil injection is a prostacyclin mimetic indicated for the treatment of pulmonary arterial hypertension (PAH;
WHO Group 1) to diminish symptoms associated with
exercise. Studies establishing effectiveness included
patients with NYHA Functional Class II-IV symptoms and
etiologies of idiopathic or heritable PAH (58%), PAH
associated with congenital systemic-to-pulmonary
shunts (23%), or PAH associated with connective tissue
diseases (19%). 
It is also indicated for patients who require transition from epoprostenol, to
reduce the rate of clinical deterioration. The risks and
benefits of each drug should be carefully considered prior
to transition.

Dr. Reddy’s Treprostinil Injection is supplied as 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL or 200 mg/20 mL vials.

Remodulin is a registered trademark of United Therapeutics Corporation.

Dr. Reddy’s Laboratories Ltd. is a global
pharmaceutical company headquartered in Hyderabad, India. Established in 1984, the company offers a portfolio of products and services
including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddys major markets include – USA, India, Russia & CIS
countries, China, Brazil and Europe.

What do you think?

Written by

Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings

SAP Plans to Use OpenAI’s Chatbot ChatGPT Amid Growth in Quarterly Revenue

Health News Live: India Records 12,193 More COVID-19 Cases And 42 Deaths In One Day